Atherosclerosis Drugs Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the atherosclerosis drugs market grown over the years?
The market size of drugs for atherosclerosis has been on a consistent growth trajectory over the years. It is projected to expand from $49.89 billion in 2024 to $51.42 billion in 2025, with a compound annual growth rate (CAGR) of 3.1%. Several factors have driven this growth in the historical period, including management strategies for cholesterol and blood pressure, initiatives to stop smoking, research and development activities, and advancements in diagnostics.
What Is the forecasted market size and growth rate for the atherosclerosis drugs market?
In the forthcoming years, the market size for atherosclerosis drugs is projected to witness consistent growth, reaching a value of $59.38 billion by 2029 with a compound annual growth rate (CAGR) of 3.7%. The anticipated growth during the forecast period can be credited to the advent of new treatment methods, precision medicine, immunotherapy, inflammation treatment advances, lipid management innovations, and regulatory backing. Other significant trends during the projection period encompass biologic therapies, gene modification and therapy, combined therapies, tailored treatment methodologies, telehealth strategies, and remote patient monitoring.
Get your atherosclerosis drugs market report here!
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
What are the major factors driving growth in the atherosclerosis drugs market?
The anticipated rise in cardiovascular diseases is expected to stimulate the growth of the atherosclerosis drug market. Cardiovascular diseases include all the disorders that can potentially affect the heart and blood vessels, with atherosclerosis being the condition that involves the accumulation of fats, cholesterol, and other substances in the artery walls of an individual. It is a syndrome marked by the formation of plaques in the arteries, leading to coronary heart disease and stroke, amongst other cardiovascular diseases. Atherosclerosis drugs are vital in managing cardiovascular diseases, as they lower the possibility of complications and control associated conditions like high cholesterol levels and clotting of blood. For example, data from the Minnesota Department of Health, a state health agency in the US, revealed in September 2024 that about 30% of adults in Minnesota, almost 1.4 million people, had high blood pressure in 2023, and in 2022, hypertensive diseases caused or contributed to 14,225 deaths, which equates to around 28% of the total deaths in the state. Consequently, the widespread occurrence of cardiovascular diseases will further stimulate the growth of the atherosclerosis drug market.
What key areas define the segmentation of the global atherosclerosis drugs Market?
The atherosclerosis drugs market covered in this report is segmented –
1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp
What are the top market players propelling the growth of the atherosclerosis drugs industry?
Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.
What are the key trends shaping the future of the atherosclerosis drugs market?
Advancements in product innovation appear as a significant trend propelling the future growth of the atherosclerosis drugs market. Major market participants are focusing on creating innovative drugs and gaining necessary approvals to maintain their market standing. To illustrate, in March 2024, Novo Nordisk A/S, a healthcare firm based in Denmark, secured approval for Wegovy (semaglutide), aimed at reducing cardiovascular risk in those with obesity or excess weight. This drug represents the first weight loss medication endorsed to mitigate the threat of significant cardiovascular incidents in adults carrying excess weight or obesity and diagnosed cardiovascular disease. It offers a fresh treatment possibility for this vulnerable group. Apart from managing obesity, this dual-function drug is crucial for averting critical cardiovascular issues, potentially enhancing patient results and extending life expectancy.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12621
What regions are dominating the atherosclerosis drugs market growth?
North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Skin Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report
Cardiac Biomarkers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report
Drugs For Benign Prostatic hypertrophy Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
